<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35398340</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-953X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>169</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurobiology of disease</Title>
          <ISOAbbreviation>Neurobiol Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Human IPSC 3D brain model as a tool to study chemical-induced dopaminergic neuronal toxicity.</ArticleTitle>
        <Pagination>
          <StartPage>105719</StartPage>
          <MedlinePgn>105719</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2022.105719</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0969-9961(22)00111-5</ELocationID>
        <Abstract>
          <AbstractText>Oxidative stress is caused by an imbalance between the generation and detoxification of reactive oxygen and nitrogen species (ROS/RNS). This imbalance plays an important role in brain aging and age-related neurodegenerative diseases. In the context of Parkinson's disease (PD), the sensitivity of dopaminergic neurons in the substantia nigra pars compacta to oxidative stress is considered a key factor of PD pathogenesis. Here we study the effect of different oxidative stress-inducing compounds (6-OHDA, MPTP or MPP<sup>+</sup>) on the population of dopaminergic neurons in an iPSC-derived human brain 3D model (aka BrainSpheres). Treatment with 6-OHDA, MPTP or MPP<sup>+</sup> at 4 weeks of differentiation disrupted the dopaminergic neuronal phenotype in BrainSpheres at (50, 5000, 1000 μM respectively). 6-OHDA increased ROS production and decreased mitochondrial function most efficiently. It further induced the greatest changes in gene expression and metabolites related to oxidative stress and mitochondrial dysfunction. Co-culturing BrainSpheres with an endothelial barrier using a transwell system allowed the assessment of differential penetration capacities of the tested compounds and the damage they caused in the dopaminergic neurons within the BrainSpheres In conclusion, treatment with compounds known to induce PD-like phenotypes in vivo caused molecular deficits and loss of dopaminergic neurons in the BrainSphere model. This approach therefore recapitulates common animal models of neurodegenerative processes in PD at similarly high doses. The relevance as tool for drug discovery is discussed.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pamies</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America; Department of Biomedical Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland. Electronic address: david.pamies@unil.ch.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wiersma</LastName>
            <ForeName>Daphne</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Katt</LastName>
            <ForeName>Moriah E</ForeName>
            <Initials>ME</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States of America; Institute of Nanobiotechnology, 100 Croft Hall, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhao</LastName>
            <ForeName>Liang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Burtscher</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Sport Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland; Department of Biomedical Sciences, University of Lausanne, CH-1015 Lausanne, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harris</LastName>
            <ForeName>Georgina</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Smirnova</LastName>
            <ForeName>Lena</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Searson</LastName>
            <ForeName>Peter C</ForeName>
            <Initials>PC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Materials Science and Engineering, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States of America; Institute of Nanobiotechnology, 100 Croft Hall, Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hartung</LastName>
            <ForeName>Thomas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America; CAAT-Europe, University of Konstanz, Universitätstsr. 10, 78464 Konstanz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hogberg</LastName>
            <ForeName>Helena T</ForeName>
            <Initials>HT</Initials>
            <AffiliationInfo>
              <Affiliation>Center for Alternative to Animal Testing, Johns Hopkins University, 615 North Wolfe St., Baltimore, MD 21205, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurobiol Dis</MedlineTA>
        <NlmUniqueID>9500169</NlmUniqueID>
        <ISSNLinking>0969-9961</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8HW4YBZ748</RegistryNumber>
          <NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9P21XSP91P</RegistryNumber>
          <NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">3d culture</Keyword>
        <Keyword MajorTopicYN="N">6OHDA</Keyword>
        <Keyword MajorTopicYN="N">MPP(+)</Keyword>
        <Keyword MajorTopicYN="N">MPTP</Keyword>
        <Keyword MajorTopicYN="N">Microphysiological system</Keyword>
        <Keyword MajorTopicYN="N">Organoid</Keyword>
        <Keyword MajorTopicYN="N">Stem cells</Keyword>
        <Keyword MajorTopicYN="N">Toxicant-induced Parkinson's disease</Keyword>
        <Keyword MajorTopicYN="N">iPSC</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>20</Hour>
          <Minute>24</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35398340</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nbd.2022.105719</ArticleId>
        <ArticleId IdType="pii">S0969-9961(22)00111-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
